LT2894162T - Su augliu siejamų antigenų identifikavimas diagnostikai ir gydymui - Google Patents

Su augliu siejamų antigenų identifikavimas diagnostikai ir gydymui

Info

Publication number: LT2894162T
Authority: LT; Lithuania
Prior art keywords: tumor; diagnosis; therapy; identification; associated antigens
Prior art date: 2005-09-12

Application number

LTEP15153951.7T

Other languages

English (en)

Inventor

Ugur Sahin

Özlem TÜRECI

Michael Koslowski

Dirk Usener

Original Assignee

Ganymed Pharmaceuticals Gmbh

Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-12

Filing date

2006-09-06

Publication date

2018-04-10

2006-09-06 Application filed by Ganymed Pharmaceuticals Gmbh, Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten filed Critical Ganymed Pharmaceuticals Gmbh

2018-04-10 Publication of LT2894162T publication Critical patent/LT2894162T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Oncology (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)

LTEP15153951.7T 2005-09-12 2006-09-06 Su augliu siejamų antigenų identifikavimas diagnostikai ir gydymui LT2894162T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP20050019786 EP1762575A1 (en)	2005-09-12	2005-09-12	Identification of tumor-associated antigens for diagnosis and therapy

Publications (1)

Publication Number	Publication Date
LT2894162T true LT2894162T (lt)	2018-04-10

Family

ID=35285406

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP15153951.7T LT2894162T (lt)	2005-09-12	2006-09-06	Su augliu siejamų antigenų identifikavimas diagnostikai ir gydymui

Country Status (21)

Country	Link
US (5)	US20090202530A1 (lt)
EP (14)	EP1762575A1 (lt)
JP (5)	JP6037593B2 (lt)
KR (2)	KR101359697B1 (lt)
CN (1)	CN101305020B (lt)
AU (1)	AU2006291717B2 (lt)
BR (1)	BRPI0616827A2 (lt)
CA (2)	CA2620712A1 (lt)
CY (3)	CY1114661T1 (lt)
DK (3)	DK2894162T3 (lt)
ES (4)	ES2532410T3 (lt)
HK (3)	HK1118840A1 (lt)
HR (3)	HRP20131047T1 (lt)
HU (1)	HUE037307T2 (lt)
LT (1)	LT2894162T (lt)
PL (3)	PL2433954T3 (lt)
PT (3)	PT1924600E (lt)
RS (3)	RS57080B1 (lt)
RU (2)	RU2485974C2 (lt)
SI (3)	SI1924600T1 (lt)
WO (1)	WO2007031222A2 (lt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10347710B4 (de)	2003-10-14	2006-03-30	Johannes-Gutenberg-Universität Mainz	Rekombinante Impfstoffe und deren Verwendung
EP1762575A1 (en)	2005-09-12	2007-03-14	Ganymed Pharmaceuticals AG	Identification of tumor-associated antigens for diagnosis and therapy
AU2013206613B2 (en) *	2005-09-12	2017-03-02	Biontech Ag	Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de)	2005-09-28	2007-03-29	Johannes-Gutenberg-Universität Mainz	Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP1970384A1 (en)	2007-03-14	2008-09-17	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
EP2060583A1 (en) *	2007-10-23	2009-05-20	Ganymed Pharmaceuticals AG	Identification of tumor-associated markers for diagnosis and therapy
AU2016201637B2 (en) *	2007-10-23	2017-05-25	Biontech Ag	Identification of tumor-associated markers for diagnosis and therapy
AU2015205868B2 (en) *	2008-09-16	2017-04-27	Ganymed Pharmaceuticals Ag	Monoclonal antibodies for treatment of cancer
EP2166021A1 (en)	2008-09-16	2010-03-24	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
EP2371864A1 (en)	2010-03-23	2011-10-05	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
US9061066B2 (en) *	2010-06-04	2015-06-23	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Immunoadjuvant compounds and uses thereof
JP6444171B2 (ja)	2011-05-24	2018-12-26	バイオンテックエールエヌアーファーマシューティカルズゲーエムベーハー	癌の個別化ワクチン
WO2013143555A1 (en)	2012-03-26	2013-10-03	Biontech Ag	Rna formulation for immunotherapy
JP6484558B2 (ja)	2012-11-28	2019-03-13	バイオエヌテックエールエヌアーファーマシューティカルズゲーエムベーハーＢｉｏｎｔｅｃｈＲｎａＰｈａｒｍａｃｅｕｔｉｃａｌｓＧｍｂｈ	癌ワクチンの組み合せ物
WO2014180490A1 (en)	2013-05-10	2014-11-13	Biontech Ag	Predicting immunogenicity of t cell epitopes
US10391115B2 (en)	2014-02-07	2019-08-27	Ajou University Industry-Academic Cooperation Foundation	Anticancer adjuvant composition containing RIP3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting RIP3 expression, and method for monitoring sensitivity of anticancer drug
WO2016040682A1 (en)	2014-09-10	2016-03-17	Genentech, Inc.	Immunogenic mutant peptide screening platform
WO2016045732A1 (en)	2014-09-25	2016-03-31	Biontech Rna Pharmaceuticals Gmbh	Stable formulations of lipids and liposomes
RU2620306C2 (ru) *	2015-01-15	2017-05-24	Олег Викторович Бухтояров	Способ прогнозирования рецидива злокачественного опухолевого заболевания
WO2016128060A1 (en)	2015-02-12	2016-08-18	Biontech Ag	Predicting t cell epitopes useful for vaccination
CN107636152B (zh) *	2015-03-16	2021-09-21	马克思-德布鲁克-分子医学中心亥姆霍兹联合会	通过mhc细胞文库检测新免疫原性t细胞表位和分离新抗原-特异性t细胞受体的方法
CA2989373A1 (en) *	2015-06-16	2016-12-22	Targovax Asa	Mutated fragments of the ras protein
GB201516047D0 (en)	2015-09-10	2015-10-28	Cancer Rec Tech Ltd	Method
WO2017059902A1 (en)	2015-10-07	2017-04-13	Biontech Rna Pharmaceuticals Gmbh	3' utr sequences for stabilization of rna
EP3389630B1 (en)	2015-12-16	2023-11-08	Gritstone bio, Inc.	Neoantigen identification, manufacture, and use
CA3008437A1 (en)	2016-01-08	2017-07-13	Vaccibody As	Therapeutic anticancer neoepitope vaccine
WO2017127716A1 (en)	2016-01-22	2017-07-27	Temple University-Of The Commonwealth System Of Higher Education	Protein quantification by near infrared spectral imaging
CN107266552B (zh) *	2016-03-30	2022-02-08	香雪生命科学技术（广东）有限公司	源自于prame的肿瘤抗原短肽
CA3024655A1 (en)	2016-05-20	2017-11-23	Arlanxeo Netherlands B.V.	Rubber composition
DE102016115246C5 (de) *	2016-08-17	2018-12-20	Immatics Biotechnologies Gmbh	Neue t-zellrezeptoren und deren verwendung in immuntherapie
CN108250289B (zh) *	2016-12-28	2021-10-08	香雪生命科学技术（广东）有限公司	源自于mage b6的肿瘤抗原短肽
TWI676483B (zh) *	2017-08-06	2019-11-11	強普生技股份有限公司	醫藥套組及其用途
EP3694532B1 (en)	2017-10-10	2025-02-26	Gritstone bio, Inc.	Neoantigen identification using hotspots
CA3083097A1 (en)	2017-11-22	2019-05-31	Gritstone Oncology, Inc.	Reducing junction epitope presentation for neoantigens
JP7082556B2 (ja)	2018-09-28	2022-06-08	三和シヤッター工業株式会社	シャッター装置

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4475196A (en) *	1981-03-06	1984-10-02	Zor Clair G	Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) *	1981-04-10	1984-05-08	Parker-Hannifin Corporation	Medication infusion pump
US4474893A (en) *	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4439196A (en) *	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4522811A (en) *	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) *	1982-09-20	1984-05-08	Infusaid Corporation	Variable flow implantable infusion apparatus
US4487603A (en) *	1982-11-26	1984-12-11	Cordis Corporation	Implantable microinfusion pump system
US4486194A (en) *	1983-06-08	1984-12-04	James Ferrara	Therapeutic device for administering medicaments through the skin
US4596556A (en) *	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US5374548A (en) *	1986-05-02	1994-12-20	Genentech, Inc.	Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) *	1985-06-26	1992-08-01	Liposome Co Inc	Metodo para acoplamiento de liposomas.
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4954617A (en)	1986-07-07	1990-09-04	Trustees Of Dartmouth College	Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) *	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en) *	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4881175A (en) *	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
AU600575B2 (en) *	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
US5013653A (en) *	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) *	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5091513A (en) *	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5258498A (en) *	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
AU612370B2 (en) *	1987-05-21	1991-07-11	Micromet Ag	Targeted multifunctional proteins
US4941880A (en) *	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) *	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
US5108921A (en) *	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) *	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5064413A (en) *	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en)	1990-09-11	1990-10-24	Scotgen Ltd	Novel antibodies for treatment and prevention of infection in animals and man
US5383851A (en) *	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
GB9223377D0 (en)	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
PT752248E (pt) *	1992-11-13	2001-01-31	Idec Pharma Corp	Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5744585A (en) *	1995-03-16	1998-04-28	Medenica; Rajko D.	Human monoclonal antibody against lung carcinoma
US6121022A (en) *	1995-04-14	2000-09-19	Genentech, Inc.	Altered polypeptides with increased half-life
US5677139A (en)	1995-04-21	1997-10-14	President And Fellows Of Harvard College	In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6277375B1 (en) *	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) *	1998-03-18	2002-05-30	Kenneth Jacobs	Secreted proteins and polynucleotides encoding them
US6194551B1 (en) *	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
GB9826143D0 (en)	1998-11-27	1999-01-20	Ludwig Inst Cancer Res	Tumour rejection antigens
CZ302801B6 (cs) *	1999-01-13	2011-11-16	Igeneon Krebs-Immuntherapie Forschungs Und Entwicklungs-Ag	Použití protilátky namírené proti antigenu bunecné membrány Ep-CAM pro výrobu farmaceutického prostredku
US6943235B1 (en) *	1999-04-12	2005-09-13	Agensys, Inc.	Transmembrane protein expressed in prostate cancer
EP2028278B1 (en)	2000-03-30	2014-03-19	Whitehead Institute For Biomedical Research	RNA sequence-specific mediators of RNA interference
US6974667B2 (en) *	2000-06-14	2005-12-13	Gene Logic, Inc.	Gene expression profiles in liver cancer
US20020192748A1 (en) *	2000-07-18	2002-12-19	Luca Rastelli	Novel polynucleotides and polypeptides encoded thereby
AU2001284703B2 (en) *	2000-08-03	2007-03-22	Therapeutic Human Polyclonals Inc.	Production of humanized antibodies in transgenic animals
US6812339B1 (en) *	2000-09-08	2004-11-02	Applera Corporation	Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
PT1354034E (pt)	2000-11-30	2008-02-28	Medarex Inc	Roedores transgénicos transcromossómicos para produção de anticorpos humanos
US20020177547A1 (en) *	2001-01-16	2002-11-28	Karin Molling	Pharmaceutical compositions for treating or preventing cancer
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) *	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
JP2005507239A (ja) *	2001-05-25	2005-03-17	インサイト・ゲノミックス・インコーポレイテッド	分泌タンパク質
WO2003016475A2 (en) *	2001-08-14	2003-02-27	The General Hospital Corporation	Nucleic acid and amino acid sequences involved in pain
WO2003075014A2 (en) *	2002-03-06	2003-09-12	Oxford Glycosciences (Uk) Ltd	Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
WO2003102159A2 (en) *	2002-06-04	2003-12-11	Curagen Corporation	Novel proteins and nucleic acids encoding same
US7053201B2 (en) *	2002-08-30	2006-05-30	National Defense Medical Center	Nucleic acid molecules and polypeptides related to h-ADAM7
TW200413539A (en) *	2002-09-30	2004-08-01	Oncotherapy Science Inc	Genes and polypeptides relating to prostate cancers
EP1558648B1 (en)	2002-10-17	2012-01-11	Genmab A/S	Human monoclonal antibodies against cd20
EP1604009A4 (en) *	2002-11-06	2007-06-20	Sequenom Inc	METHOD FOR IDENTIFYING MELANOMA RISK AND TREATMENTS THEREOF
US7235359B2 (en) *	2003-01-17	2007-06-26	The Chinese University Of Hong Kong	Method for diagnosing preeclampsia by detecting hCRH mRNA
WO2004072265A2 (en) *	2003-02-11	2004-08-26	Wyeth	Methods for monitoring drug activities in vivo
WO2005049806A2 (en) *	2003-03-14	2005-06-02	Nuvelo, Inc.	Novel nucleic acids and polypeptides
US20050255114A1 (en) *	2003-04-07	2005-11-17	Nuvelo, Inc.	Methods and diagnosis for the treatment of preeclampsia
RU2256924C2 (ru) *	2003-09-03	2005-07-20	Торопова Надежда Ефимовна	Способ дифференциальной диагностики злокачественных опухолей простаты
WO2005079490A2 (en) *	2004-02-13	2005-09-01	Nuvelo, Inc.	Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
CN1663603A (zh) *	2004-03-02	2005-09-07	北京大学	一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en)	2005-09-12	2007-03-14	Ganymed Pharmaceuticals AG	Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en)	2007-03-14	2008-09-17	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) *	2008-09-16	2010-03-24	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer
EP2221063A1 (en) *	2009-02-20	2010-08-25	Ganymed Pharmaceuticals AG	Methods and compositions for diagnosis and treatment of cancer
EP2398902B1 (en) *	2009-02-20	2023-10-04	Astellas Pharma Inc.	Methods and compositions for diagnosis and treatment of cancer
EP2371864A1 (en)	2010-03-23	2011-10-05	Ganymed Pharmaceuticals AG	Monoclonal antibodies for treatment of cancer

2005
- 2005-09-12 EP EP20050019786 patent/EP1762575A1/en not_active Withdrawn
2006
- 2006-09-06 EP EP20110003888 patent/EP2433959A3/en not_active Withdrawn
- 2006-09-06 SI SI200631679T patent/SI1924600T1/sl unknown
- 2006-09-06 RS RS20180353A patent/RS57080B1/sr unknown
- 2006-09-06 ES ES11003887.4T patent/ES2532410T3/es active Active
- 2006-09-06 US US12/066,399 patent/US20090202530A1/en not_active Abandoned
- 2006-09-06 PT PT67918789T patent/PT1924600E/pt unknown
- 2006-09-06 RS RS20130469A patent/RS53009B/en unknown
- 2006-09-06 RS RS20150290A patent/RS53988B1/en unknown
- 2006-09-06 LT LTEP15153951.7T patent/LT2894162T/lt unknown
- 2006-09-06 PL PL11003883T patent/PL2433954T3/pl unknown
- 2006-09-06 DK DK15153951.7T patent/DK2894162T3/en active
- 2006-09-06 RU RU2008114318/10A patent/RU2485974C2/ru not_active IP Right Cessation
- 2006-09-06 EP EP15153951.7A patent/EP2894162B1/en active Active
- 2006-09-06 SI SI200632252T patent/SI2894162T1/en unknown
- 2006-09-06 EP EP20110003883 patent/EP2433954B8/en active Active
- 2006-09-06 WO PCT/EP2006/008695 patent/WO2007031222A2/en active Application Filing
- 2006-09-06 CN CN200680041875.XA patent/CN101305020B/zh not_active Expired - Fee Related
- 2006-09-06 CA CA002620712A patent/CA2620712A1/en not_active Abandoned
- 2006-09-06 PT PT110038833T patent/PT2433954E/pt unknown
- 2006-09-06 EP EP06791878.9A patent/EP1924600B1/en active Active
- 2006-09-06 EP EP20110003886 patent/EP2433957A3/en not_active Withdrawn
- 2006-09-06 JP JP2008530387A patent/JP6037593B2/ja not_active Expired - Fee Related
- 2006-09-06 HU HUE15153951A patent/HUE037307T2/hu unknown
- 2006-09-06 EP EP20110003889 patent/EP2433960B1/en active Active
- 2006-09-06 SI SI200631922T patent/SI2433954T1/sl unknown
- 2006-09-06 PT PT151539517T patent/PT2894162T/pt unknown
- 2006-09-06 EP EP15160484.0A patent/EP2966082B1/en active Active
- 2006-09-06 ES ES06791878T patent/ES2434945T3/es active Active
- 2006-09-06 EP EP20110003890 patent/EP2433961A3/en not_active Withdrawn
- 2006-09-06 KR KR1020087008926A patent/KR101359697B1/ko active IP Right Grant
- 2006-09-06 ES ES15153951.7T patent/ES2664386T3/es active Active
- 2006-09-06 CA CA2820201A patent/CA2820201C/en active Active
- 2006-09-06 EP EP20110003887 patent/EP2433958B1/en active Active
- 2006-09-06 DK DK11003883T patent/DK2433954T3/en active
- 2006-09-06 EP EP20110003885 patent/EP2433956A3/en not_active Withdrawn
- 2006-09-06 EP EP20110003884 patent/EP2433955A3/en not_active Withdrawn
- 2006-09-06 BR BRPI0616827-2A patent/BRPI0616827A2/pt not_active Application Discontinuation
- 2006-09-06 AU AU2006291717A patent/AU2006291717B2/en not_active Ceased
- 2006-09-06 KR KR1020137026645A patent/KR20130121198A/ko not_active Application Discontinuation
- 2006-09-06 EP EP20110003891 patent/EP2433962B1/en active Active
- 2006-09-06 PL PL06791878T patent/PL1924600T3/pl unknown
- 2006-09-06 DK DK06791878.9T patent/DK1924600T3/da active
- 2006-09-06 EP EP15156794.8A patent/EP2902412B1/en active Active
- 2006-09-06 ES ES11003883.3T patent/ES2535500T3/es active Active
- 2006-09-06 PL PL15153951T patent/PL2894162T3/pl unknown
2008
- 2008-11-21 HK HK08112789.2A patent/HK1118840A1/xx not_active IP Right Cessation
- 2008-11-21 HK HK12109409.2A patent/HK1168608A1/xx unknown
2011
- 2011-04-13 US US13/086,176 patent/US8975375B2/en not_active Expired - Fee Related
2012
- 2012-12-28 JP JP2012288124A patent/JP5750433B2/ja active Active
2013
- 2013-03-26 RU RU2013113439A patent/RU2644686C2/ru not_active IP Right Cessation
- 2013-07-19 US US13/946,302 patent/US20140017254A1/en not_active Abandoned
- 2013-11-05 HR HRP20131047TT patent/HRP20131047T1/hr unknown
- 2013-11-13 CY CY20131101005T patent/CY1114661T1/el unknown
2014
- 2014-12-17 JP JP2014254806A patent/JP5913547B2/ja active Active
2015
- 2015-01-27 US US14/606,729 patent/US9919036B2/en active Active
- 2015-04-21 HR HRP20150432TT patent/HRP20150432T1/hr unknown
- 2015-04-30 CY CY20151100395T patent/CY1116951T1/el unknown
- 2015-11-24 JP JP2015228705A patent/JP2016102116A/ja active Pending
- 2015-12-18 HK HK15112513.6A patent/HK1211606A1/xx unknown
2016
- 2016-02-15 JP JP2016025541A patent/JP6196338B2/ja active Active
- 2016-07-27 US US15/220,973 patent/US20170080068A1/en not_active Abandoned
2018
- 2018-03-27 HR HRP20180507TT patent/HRP20180507T1/hr unknown
- 2018-03-27 CY CY20181100344T patent/CY1120096T1/el unknown

Also Published As

Publication number	Publication date
EP2902412B1 (en)	2018-02-21
US20150197576A1 (en)	2015-07-16
HRP20150432T1 (hr)	2015-09-25
EP2433954B1 (en)	2015-02-25
CY1116951T1 (el)	2017-04-05
PT1924600E (pt)	2013-11-18
KR20080052664A (ko)	2008-06-11
CN101305020A (zh)	2008-11-12
DK2433954T3 (en)	2015-05-04
PT2894162T (pt)	2018-04-02
EP2433954B8 (en)	2015-05-13
HRP20131047T1 (hr)	2013-12-06
BRPI0616827A2 (pt)	2011-07-05
PL2894162T3 (pl)	2018-06-29
JP5913547B2 (ja)	2016-04-27
EP2433957A3 (en)	2012-07-04
EP2433955A2 (en)	2012-03-28
EP2966082A1 (en)	2016-01-13
EP1924600A2 (en)	2008-05-28
KR101359697B1 (ko)	2014-02-07
EP2433961A2 (en)	2012-03-28
SI1924600T1 (sl)	2013-12-31
HK1118840A1 (en)	2009-02-20
US20090202530A1 (en)	2009-08-13
JP5750433B2 (ja)	2015-07-22
EP2433962A2 (en)	2012-03-28
EP2894162B1 (en)	2018-01-03
EP2433958B1 (en)	2015-02-25
EP1924600B1 (en)	2013-08-28
PL2433954T3 (pl)	2015-07-31
EP2894162A1 (en)	2015-07-15
US20170080068A1 (en)	2017-03-23
WO2007031222A3 (en)	2007-07-26
RU2485974C2 (ru)	2013-06-27
JP2016102116A (ja)	2016-06-02
AU2006291717A1 (en)	2007-03-22
PL1924600T3 (pl)	2014-01-31
RS53009B (en)	2014-04-30
EP2433957A2 (en)	2012-03-28
EP2433962B1 (en)	2015-03-25
DK1924600T3 (da)	2013-11-11
RS53988B1 (en)	2015-10-30
EP2433954A3 (en)	2012-07-04
EP2433959A2 (en)	2012-03-28
EP2433954A2 (en)	2012-03-28
CY1120096T1 (el)	2018-12-12
EP2433955A3 (en)	2012-07-04
EP1762575A1 (en)	2007-03-14
RS57080B1 (sr)	2018-06-29
DK2894162T3 (en)	2018-04-16
US20110189179A1 (en)	2011-08-04
ES2535500T3 (es)	2015-05-12
CA2820201C (en)	2018-07-17
HK1211606A1 (en)	2016-05-27
ES2664386T3 (es)	2018-04-19
EP2433958A3 (en)	2012-07-04
US9919036B2 (en)	2018-03-20
JP2009507868A (ja)	2009-02-26
EP2433960B1 (en)	2015-03-04
EP2966082B1 (en)	2017-08-30
RU2644686C2 (ru)	2018-02-13
RU2008114318A (ru)	2009-10-20
EP2433959A3 (en)	2012-06-27
HUE037307T2 (hu)	2018-08-28
US20140017254A1 (en)	2014-01-16
RU2013113439A (ru)	2014-10-10
CY1114661T1 (el)	2016-10-05
JP2015120691A (ja)	2015-07-02
AU2006291717B2 (en)	2013-06-06
EP2433960A3 (en)	2012-07-04
SI2433954T1 (sl)	2015-06-30
JP2016166175A (ja)	2016-09-15
HK1168608A1 (en)	2013-01-04
HRP20180507T1 (hr)	2018-05-04
JP6037593B2 (ja)	2016-12-07
CN101305020B (zh)	2015-09-02
JP2013136579A (ja)	2013-07-11
ES2434945T3 (es)	2013-12-18
EP2433960A2 (en)	2012-03-28
PT2433954E (pt)	2015-06-02
WO2007031222A2 (en)	2007-03-22
CA2820201A1 (en)	2007-03-22
JP6196338B2 (ja)	2017-09-13
CA2620712A1 (en)	2007-03-22
EP2433956A2 (en)	2012-03-28
EP2902412A1 (en)	2015-08-05
EP2433962A3 (en)	2012-07-04
EP2433961A3 (en)	2012-06-27
ES2532410T3 (es)	2015-03-26
SI2894162T1 (en)	2018-05-31
EP2433958A2 (en)	2012-03-28
EP2433956A3 (en)	2012-07-04
KR20130121198A (ko)	2013-11-05
US8975375B2 (en)	2015-03-10

Publication	Publication Date	Title
HK1211606A1 (en)	2016-05-27	Identification of tumor-associated antigens for diagnosis and therapy
IL225386A0 (en)	2013-06-27	Diagnosis and treatment of cancer using anti-ereg antibody
HUS1700015I1 (hu)	2017-07-28	PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél
EP1814909A4 (en)	2008-06-25	USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1811844A4 (en)	2009-12-02	METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
HRP20140271T1 (hr)	2014-05-23	Humana antitijela protiv bjesnoä†e i njihova uporaba
PT1814580T (pt)	2016-11-11	Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais
HK1199887A1 (en)	2015-07-24	Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49
IL185491A0 (en)	2008-01-06	Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
EP1718145A4 (en)	2012-03-07	CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
IL179811A0 (en)	2007-05-15	Identification of tumors
EP1937816A4 (en)	2008-11-05	CANCER DIAGNOSTIC MARKERS AND USE
HK1164767A1 (en)	2012-09-28	Compounds and methods for the treatment of cancer
EP1742654A4 (en)	2009-01-21	ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER
IL185900A0 (en)	2008-01-06	Compositions and methods for the diagnosis and treatment of tumor
ZA200706159B (en)	2008-10-29	Compositions and methods for the diagnosis and treatment of tumor
IL201880A0 (en)	2010-06-16	Klotho protein and related compounds for the treatment and diagnosis of cancer
GB0511078D0 (en)	2005-07-06	Means and methods of verification of entitlement and identification
GB0421917D0 (en)	2004-11-03	Cancer diagnosis and therapy
ZA200710321B (en)	2009-08-26	Compositions and methods for the diagnosis and treatment of tumor